Heart failure and cardiac hypertrophy

Current Treatment Options in Cardiovascular Medicine

Volumn 9, Issue 4, 2007, Pages 289-301

  Rame, J Eduardo ^a   Dries, Daniel L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; EPLERENONE; FLUCONAZOLE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LITHIUM; LOOP DIURETIC AGENT; LOSARTAN; LOSARTAN POTASSIUM; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MINOXIDIL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VOSOTEC;

ABDOMINAL PAIN; ALOPECIA; AMENORRHEA; AMNESIA; ANEMIA; ANOREXIA; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL INSUFFICIENCY; ATAXIA; BACKACHE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLURRED VISION; BOLUS INJECTION; BONE DISEASE; BRADYCARDIA; BRONCHITIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DIABETIC NEPHROPATHY; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; EAR DISEASE; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; EOSINOPHILIA; EPIGASTRIC DISCOMFORT; ERYTHEMA; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; FATIGUE; FEVER; FLATULENCE; FLUID RETENTION; FOOD DRUG INTERACTION; GANGRENE; GASTROINTESTINAL PAIN; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GOUT; GRAPEFRUIT; GYNECOMASTIA; HEADACHE; HEARING IMPAIRMENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HEART VENTRICLE HYPERTROPHY; HEART VOLUME; HEARTBURN; HEMATOLOGIC DISEASE; HIRSUTISM; HUMAN; HYPERCHLOREMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; IMMUNE COMPLEX NEPHRITIS; IMPOTENCE; INSOMNIA; INTRAHEPATIC CHOLESTASIS; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LETHARGY; LIBIDO; LIFESTYLE MODIFICATION; LIVER ISCHEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; MACULOPAPULAR RASH; MASTALGIA; MENSTRUAL IRREGULARITY; MENTAL DISEASE; METABOLIC ACIDOSIS; METABOLIC DISORDER; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NEUROMUSCULAR DISEASE; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARESTHESIA; PERIPHERAL EDEMA; PEYRONIE DISEASE; PHOTOSENSITIVITY; PRURITUS; PSORIASIS; PURPURA; RASH; RAYNAUD PHENOMENON; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SOMNOLENCE; STOMACH IRRITATION; SYNCOPE; TASTE DISORDER; THORAX PAIN; TINNITUS; UREA NITROGEN BLOOD LEVEL; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URTICARIA; VASCULITIS; VERTIGO; XANTHOPSIA; XEROSTOMIA;

EID: 34547502758     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-007-0024-3     Document Type: Review

References (26)

1. Pfeffer JM, Pfeffer MA, Mirsky I, et al.: Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A 1982, 79:3310-3314.
2. Litwin SE, Katz SE, Weinberg EO, et al.: Serial echocardiographic Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Circulation 1995, 91:2642-2654.
3. Molkentin JD, Lu JR, Antos CL, et al.: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
4. Rame JE, Ramilo M, Spencer N, et al.: Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol 2004, 93:234-237.
5. Drazner MH, Rame JE, Marino EK, et al.: Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection within five years. The Cardiovascular Health Study. J Am Coll Cardiol 2004, 43:2207-2215.
6. Klapholz M, Maurer M, Lowe AM, et al.: Hospitalization for Heart Failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004, 43:1432-1438.
7. Vasan R, Larson MG, Benjamin EJ, et al.: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948-1955.
8. Topol EJ, Traill TA, Fortuin NJ, et al.: Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985, 312:277-283.
9. Levy D, Salomon M, Agostino RB, et al.: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994, 90:1786-1793.
10. Muiesan ML, Salvett M, Rizzoni D, et al.: Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995, 13:1091-1105.
11. Verdecchia P, Schillaci G, Borgioni C, et al.: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998, 97:48-54.
12. Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615-1621.
13. Moser M, Herbert PR: Prevention of disease progression. LVH and CHF in hypertension treatment trials. J Am Coll Cardiol 1996, 27:1214-1217.
14. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289:2560-2572.
15. Dahlof B, Devereux RB, Kjeldsen S, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Lancet 2002, 359:995-1003.
16. Devereux RB, Dahlof B, Gerdts S, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456-1462.
17. Adami GF, Cordera R, Camerini G, et al.: Recovery of insulin sensitivity in obese patients at short term after biliopancreatic diversion. J Surg Res 2003, 113:217-221.
18. Molina A, Vendrell J, Gutierrez C: Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003, 13:615-621.
19. Karason K, Wallentin I, Larsson B, et al.: Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. BMJ 1997, 315:912-916.
20. Ikonomidis I, Mazarakis A, Papadopoulos C, et al.: Weight loss after bariatric surgery improves aortic elastic properties and left ventricular function in individuals with morbid obesity: a three year follow-up study. J Hypertens 2007, 25:439-447.
21. Dahlof B, Pennert K, Hansson L, et al.: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992, 5:95-110.
22. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41-46.
23. Carson P, Massie BM, Mckelvie R, et al.: The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005, 11:576-585.
24. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
25. Hjalmarson A, Goldstein S, Fagerberg B, et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000, 283:1295-1302.
26. Pitt B, Remme W, Zannad F: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.